Document is current

Article History

Received: 20 July 2020

Accepted: 2 October 2020

First Online: 27 October 2020

Ethics approval and consent to participate

: Study approval was obtained from the Institutional Review Boards of both Emory University (IRB00084299) and Georgia Institute of Technology (H16120). Patients provided informed written consent for enrollment and agreed to any use of their data for publication.

: Part of the consent form included a statement about “sharing data with other researchers.” Patients also understood and signed in the consent document that “the study results may be used to help others in the future and may find a better way to detect lymphedema at an earlier stage than our current methods currently do.” Finally, the consent document (signed by the patient) stated that “the patient’s name and other identifying information will not appear when we present or publish the study results.”

: Three of the authors on this paper have pertinent financial interests to disclose. J. Brandon Dixon and Michael J. Weiler invented the LymphaTech technology used in this study and they are eligible to receive royalties under the license agreement with Lymphatech. Dr. Dixon, Dr. Weiler, and Mr. Nathan D. Frank own equity in LymphaTech and Dr. Dixon serves as a scientific advisor to the company. The remaining authors (BW, IL, LK, JB, PS, JO, KB, ASL, and SGM) declare that they have no competing interests.